DEF: Galectin Therapeutics Sets 2025 Annual Meeting Agenda

Galectin Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 3, 2025, to vote on director elections, executive compensation, auditor ratification, and other business.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Wednesday, December 3, 2025, at 11:00 a.m. Eastern Standard Time.
• Key proposals for the meeting include the election of eleven director nominees, a non-binding advisory resolution to approve executive compensation, a non-binding advisory vote on the frequency of future executive compensation votes, and the ratification of Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year 2025.
• The Board of Directors recommends conducting stockholder advisory votes on executive compensation every three years.
• The record date for stockholders entitled to vote at the meeting is October 7, 2025.
• The company is utilizing a virtual-only format for the annual meeting to achieve cost savings and other efficiencies.
• Directors and executive officers collectively own or control 12,288,534 shares of Common Stock or common equivalent, representing approximately 19% of the total outstanding voting shares as of the record date.
• Net Income for 2024 was $(47.2) million, compared to $(44.8) million in 2023 and $(38.9) million in 2022.
• Total Shareholder Return (TSR) for an initial $100 investment was $77.71 in 2024, a decrease from $146.90 in 2023, but an increase from $54.59 in 2022.

Sentiment

Score: 4

Explanation: While the company is conducting routine governance and has a clear compensation strategy, the persistent negative net income and reliance on significant related-party debt financing, which carries substantial dilution risk, indicate underlying financial weakness and risks. The fluctuating Total Shareholder Return also suggests volatility.

Positives

• The virtual meeting format offers cost savings and efficiencies, aiming to facilitate broader stockholder attendance and participation.
• The Board of Directors recommends voting FOR all key proposals, indicating internal alignment and confidence in current governance and compensation structures.
• Restricted stock units for named executive officers (Joel Lewis, Jack W. Callicutt, Khurram Jamil) vested on December 20, 2024, upon the company presenting top-line results from its NAVIGATE clinical trial by the end of 2024, indicating a milestone achievement.
• The company has adopted robust corporate governance policies, including a clawback policy for incentive-based compensation and an insider trading policy, promoting ethical behavior and compliance.

Negatives

• Net Income has shown a consistent negative trend, worsening from $(38.9) million in 2022 to $(44.8) million in 2023, and further to $(47.2) million in 2024.
• Total Shareholder Return (TSR) for an initial $100 investment decreased significantly from $146.90 in 2023 to $77.71 in 2024, indicating a decline in shareholder value during the most recent fiscal year.
• The company has not adopted a policy regarding the ability of officers, directors, and employees to purchase financial instruments that hedge or offset decreases in the market value of the company's equity securities.
• Significant reliance on a single related party, Richard E. Uihlein, for multiple debt financing arrangements, which could lead to substantial dilution upon conversion of convertible notes and lines of credit.

Risks

• Potential for significant dilution of existing common stock due to the conversion of multiple convertible promissory notes and lines of credit held by Richard E. Uihlein.
• Heavy financial reliance on a single related party (Richard E. Uihlein) for working capital needs through various debt financing arrangements.
• Broker non-votes on non-routine matters (director elections, say-on-pay, frequency of say-on-pay votes) could impact voting outcomes, especially as some brokerage firms have eliminated discretionary voting even for routine matters.
• Ongoing negative net income indicates persistent financial challenges and a need for continued funding.

Future Outlook

The company intends to continue evaluating its executive compensation program to ensure competitiveness and retention of key employees, particularly during the NAVIGATE clinical trial and as data from it is analyzed. The Board of Directors will consider the outcome of the non-binding advisory vote on executive compensation frequency when making future decisions. Voting results for the 2025 Annual Meeting will be reported on Form 8-K within four business days.

Management Comments

• Joel Lewis, President and CEO: "Your vote is very important. Regardless of whether you plan to virtually attend the 2025 Annual Meeting, please promptly vote your shares."
• Joel Lewis, President and CEO: "The 2025 Annual Meeting has been designed to provide the same rights to participate as you would have at an in-person meeting."
• Jack W. Callicutt, Chief Financial Officer and Corporate Secretary: "Therefore, we urge every shareholder to vote their shares." (Regarding broker non-votes).

Industry Context

The company operates within the life sciences and healthcare industry, with a clear focus on clinical development, as evidenced by the mention of the 'NAVIGATE clinical trial' and the appointment of a Chief Medical Officer with expertise in hepatology and drug development. Its executive compensation strategy is benchmarked against competitor companies of similar size and stage within this industry, indicating a competitive environment for talent.

Comparison to Industry Standards

• The executive compensation program aims to target at least the 50th percentile of total compensation programs of competitor companies in the life sciences industry. No specific comparable companies, projects, or results are listed in the filing.

Management Changes

Corporate Governance

Related Party Transactions

• Richard E. Uihlein (Chairman) provided a $10 million convertible promissory note (April 2021 Note) convertible at $5.00 per share, maturing April 16, 2025. Mr. Uihlein elected to convert this note effective April 16, 2025.
• Richard E. Uihlein provided an additional $20 million debt financing through two convertible promissory notes (September 2021 Note and December 2021 Note) with conversion prices of $8.64 and $5.43 per share, maturing September 17, 2025, and December 20, 2025, respectively.
• Richard E. Uihlein provided a Line of Credit of up to $60 million (July 2022 Credit Agreement), convertible into common stock at the closing price on the draw date (not less than $3.00 per share), with principal and interest due by January 31, 2026. Warrants to purchase up to 1,700,000 shares were issued.
• Richard E. Uihlein provided a Supplemental Line of Credit of up to $10 million (March 2024 Supplemental Credit Agreement), convertible into common stock at the closing price on the draw date (not less than $3.00 per share), with principal and interest due by March 31, 2026. Warrants to purchase up to 200,000 shares were issued.
• Richard E. Uihlein provided an additional Supplemental Line of Credit of up to $6 million (November 2024 Supplemental Credit Agreement), convertible into common stock at the closing price on the draw date (not less than $3.00 per share), with principal and interest due by March 31, 2026. Warrants to purchase up to 120,000 shares were issued.
• Richard E. Uihlein provided a Supplemental Line of Credit of up to $10 million (July 2025 Supplemental Credit Agreement), convertible into common stock at the closing price on the draw date (not less than $3.00 per share), with principal and interest due by September 30, 2026. Warrants to purchase up to 200,000 shares were issued.
• Maturity dates for all Convertible Notes Payable and Convertible Lines of Credit with Richard E. Uihlein were extended to September 30, 2026, via the July 2025 Supplemental Credit Agreement.
• Richard E. Uihlein elected to receive restricted stock in lieu of cash retainer for his director service in 2024, with the shares vesting in full on December 31, 2024.

Stakeholder Impact

• Shareholders: Will participate in key governance decisions at the 2025 Annual Meeting, including director elections and executive compensation. Face potential dilution from the conversion of significant related-party debt. Are impacted by the company's ongoing negative net income and fluctuating Total Shareholder Return.
• Employees/Executives: Benefit from a competitive total compensation package designed to attract, retain, and reward, including base salary, performance bonuses, and long-term equity awards. Subject to a clawback policy for incentive-based compensation and an insider trading policy.
• Creditors: Richard E. Uihlein is a significant creditor, providing substantial debt financing through multiple convertible notes and lines of credit, with extended maturity dates.

Next Steps

• Stockholders are encouraged to vote their shares promptly for the 2025 Annual Meeting.
• The 2025 Annual Meeting will be held virtually on December 3, 2025, where stockholders can listen, vote, and submit questions.
• The company will report voting results on Form 8-K within four business days after the 2025 Annual Meeting.
• The Board of Directors will consider the outcome of the non-binding advisory vote on executive compensation frequency when making future decisions.
• Stockholder proposals for the 2026 annual meeting must be submitted by June 24, 2026 (Rule 14a-8) or between August 5, 2026, and September 4, 2026 (outside Rule 14a-8).

Key Dates

Recommendation

While the company is addressing routine corporate governance and has a clear compensation strategy, the persistent negative net income and reliance on significant related-party debt financing, which carries substantial dilution risk, suggest underlying financial challenges. The fluctuating Total Shareholder Return also indicates volatility. Investors should hold and monitor the company's financial performance and progress on clinical trials, particularly the NAVIGATE trial, before making further investment decisions.

Keywords

Galectin Therapeutics, SEC filing, Proxy Statement, GALT, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Shareholder Vote, Convertible Notes, Clinical Trial, NAVIGATE, Biotechnology, Pharmaceutical, Financial Reporting